Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of icotrokinra for moderately to severely active ulcerative colitis
MOH_2025-09-21_014355Phase 3Recruiting
- Sponsor
- Johnson & Johnson
- Start
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in autoimmune colitis (5 arms), sponsored by Johnson & Johnson. Primary endpoints: Clinical remission induction in adults, Clinical remission maintenance in adults and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
icotrokinra
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2025-09-21_014355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-21_014355.